Sponsored Article Image

A message from Curtiss-Wright

High-Temperature neutron flux detectors for Generation IV reactors and SMRs

Learn More

Research & Applications

Bruce Power receives regulatory approval to produce medical Lu-177

September 29, 2021, 9:27AMNuclear News
The Bruce nuclear power plant in Ontario, Canada. (Photo: Bruce Power)

Bruce Power has received approval from the Canadian Nuclear Safety Commission (CNSC) to begin the production of lutetium-177, becoming the first power reactor globally to commercially produce the medical radioisotope. Isogen, a joint venture between Framatome and Kinectrics, will produce Lu-177 at Bruce’s eight-unit CANDU nuclear power plant in Ontario, Canada, using Isogen’s isotope production system (IPS).

To continue reading, log in or create a free account!

Related Articles

Saskatchewan expands its nuclear plans

January 30, 2026, 12:21PMNuclear News

This week, the government of Saskatchewan, alongside electric utility SaskPower, announced plans to formally evaluate the deployment of large nuclear technologies. This process will take place...

A trip abroad

November 17, 2025, 7:01AMNuclear NewsHash Hashemian

In my August column in Nuclear News, I reflected on the importance of ANS’s annual conferences for bringing together our nuclear community at the national level. In September, after speaking...